Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Background & Aims Despite the increased numbers of older adults with inflammatory bowel
diseases (IBDs), there are few studies regarding the safety and effectiveness of IBD …

Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

There are no prospective, head-to-head, controlled trials comparing the efficacy and safety
of Infliximab (IFX) and Vedolizumab (VDZ) for the treatment of moderate-to-severe ulcerative …

Background and Aims We conducted a retrospective cohort study comparing the risk of
serious infections between patients treated with tumor necrosis factor-a (TNFa) antagonists …

During past years, the increasing knowledge of molecular mechanisms of inflammatory
bowel disease (IBD) have led to the development of several targeted biological therapies …

Background The comparative long-term survival of first-line biologics for UC and reasons for
drug discontinuation are poorly understood. We sought to compare the long-term drug …

Background This observational real‐world evidence (RWE) study is based on prospectively
collected data from the VEDOIBD registry study. Aim To compare the effectiveness of …